TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 16 years old and up~* Performance Status 70 percent or above~* Patients should have the following diseases:~* Acute myelogenous leukemia (AML)~* Acute lymphocytic leukemia or lymphoblastic lymphoma (ALL)~* Transfusion dependent myelodysplastic syndrome (MDS)~* Non-Hodgkin's Lymphoma (NHL)~* Chronic lymphocytic leukemia (CLL)~* Pulmonary function as measured by forced expiratory volume at one second (FEV1) and/or corrected diffusing capacity of lung for carbon monoxide (DLCO) at 60 percent of predicted or above~* Left ventricular ejection fraction at 45 percent or above~* If the donor-specific HLA antibodies (DSA) are positive, the patient must undergo a desensitization protocol resulting in undetectable DSA prior to day of transplant~Exclusion Criteria:~* Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning (except for hydroxyurea)~* Uncontrolled bacterial, fungal or viral infections at time of study enrollment~* Positive for HIV, human T-cell leukemia virus (HTLV-1) and/or Hepatitis C~* Subjects with signs/symptoms of active central nervous system (CNS) disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- All patients will receive Haploidentical (Type: EXPERIMENTAL): The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone of the immunosuppression treatment to prevent GVHD. All patients will receive a Haplo-identical stem cell transplantation.~GVHD Prevention Treatment:~Cyclophosphamide 50mg/kg will be administered IV on Day 3 and Day 5 post transplant.~Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth starting on day of transplant and continue approximately 100 days post-transplant.~Mycophenolate mofetil 15mg/kg will be administered twice a day IV until patient can take it by mouth starting on Day 1 post transplant until 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Integrative Cardiac Health Project Cognitive-Behavior Therapy for Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older, Tricare beneficiary, participation in ICHP~* Sleep-onset or maintenance insomnia, defined as sleep-onset latency (SOL; time it takes to fall asleep) and/or wake after sleep onset (WASO; time spent awake after falling asleep) longer than 30 minutes per night at least 3 nights per week~* Insomnia duration of at least 3 months~* A complaint of at least 1 negative effect during waking hours (e.g., fatigue, impaired functioning, mood disturbances) that is attributed to insomnia~* Score of 8 or greater on the Insomnia Severity Index~* Pittsburgh Sleep Quality Index (PSQI) score of \> 5~Exclusion Criteria:~* Previous participation in the ICHP program~* Use of stimulant medications or acute high dose of steroids~* Suicidal ideation, as determined by a score of 1 or greater on question #9 of the Patient Health Questionnaire-9 (PHQ-9)~* Concurrent psychological or behavioral treatment for insomnia~* Current pregnancy by history, or plans to become pregnant in the next 6 months (excluded because of sleep difficulties which often occur during pregnancy that could confound the results)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ICHP + CBT-I (Type: EXPERIMENTAL): Participants in this arm will receive the usual care (ICHP program) plus 6 Cognitive-Behavior Therapy for Insomnia (CBT-I) treatment sessions. Four of the treatment sessions will be in person and two will be over the phone.
- ICHP Only (Type: NO_INTERVENTION): Participants in this arm will receive the usual care (ICHP program).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologic diagnosis of breast carcinoma~* Stage IV (M1) disease~* Adult (18 years of age or older) patients~Exclusion Criteria:~* Patients treated with a taxane within the past year~* Patients whose tumor tissue is known to show over expression of HER2/neu

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Taxol (Type: ACTIVE_COMPARATOR): Taxol 80mg/m2/week
- TOCOSOL (Type: EXPERIMENTAL): TOCOSOL Paclitaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven IgA nephropathy~* GFR \> 30 mL/min~* Urinary protein \> 700 mg/day~* Stable serum creatinine~* Urine CCL2/creatinine \> 250 pg/mg~* Stable doses of medications~* ACEI and/or ARB maximized to control hypertension and proteinuria~Exclusion Criteria:~* Other causes of nephropathy~* Pregnant or nursing females~* Prednisone \> 10 mg/day~* Other prohibited medications~* BP \> 140/90~* BMI \> 35~* Concurrent infection requiring treatment~* Clinical significant concurrent medical conditions~* Known allergy or sensitivity to formulation ingredients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: STAT3 in T Cells: At The Crossroads of Inflammation and Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with CTCL that are starting new form of treatment and adult patients with benign dermatoses.~Exclusion Criteria:~* patients with lymphomas other than CTCL or leukemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Exhaled Nitric Oxide in Conjunction With the Asthma Control Test to Determine Asthma Control in Pediatric Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of asthma by pediatric pulmonologist~* Age 6-18 years~Exclusion Criteria:~* Age \<6 years or \>18 years~* history of bronchopulmonary dysplasia~* history of cystic fibrosis~* history of primary ciliary dyskinesia~* current acute asthma exacerbation~* current acute viral upper respiratory infection~* recent ingestion of nitrate-rich foods

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Pediatric patients with previously diagnosed asthma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Metabolomics Study of Exhaled Breath in Pulmonary Embolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, at least 18 years old~* Patients with clinical suspected pulmonary embolism~* Patient willing and able to provide informed consent~Exclusion Criteria:~* Contraindications to pulmonary ventilator-perfusion tomoscintigraphy~* All types of thrombolytic or anticoagulant treatment~* Diagnosis of pulmonary embolism established prior to inclusion in the study~* Massive pulmonary embolism (systolic pressure \< 90 mm Hg)~* Pregnancy~* Breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Presence of pulmonary embolism (Type: None): ≥ 1 noninfused and normoventilated segment(s) by pulmonary tomoscintigraphy
- No pulmonary embolism (Type: None): Pulmonary perfusion without anomaly (segmental or sub-segmental) by pulmonary tomoscintigraphy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females between 18 and 59 years of age.~2. Seasonal allergic rhinitis by clinical history, with symptoms of impaired olfaction.~3. Positive skin or RAST test to allergen.~4. Symptoms of olfactory dysfunction.~5. No significant history of chronic sinusitis.~Exclusion Criteria:~1. Women of childbearing potential not using the contraception method(s) (Birth control pills, depo Provera, double barrier) as well as women who are breastfeeding.~2. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (heart, lung, kidney, neurological, oncologic or liver disease).~3. Use of any other investigational agent in the last 30 days.~4. Absence of olfactory or nasal symptoms.~5. Use of medications that may affect olfaction.~6. Medical conditions that may affect olfaction.~7. Smoking.~8. URI at the time of screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Mometasone (Type: ACTIVE_COMPARATOR): Mometasone intranasal steroid therapy daily for 2 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 2 puffs of placebo spray in each nostril once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fostering Inmates' Well-being and Mental Health

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* any inmate with no history of drug or alcohol abuse~* recreational drug users who have refrained from using drugs for two weeks before learning the meditation technique~* alcohol or drug addicts who are recovering from alcohol or drug use and have refrained from drug use for at least three months before taking part to the programme~Exclusion Criteria:~* informed consent not signed.~* expected stay in HMP Warren Hill shorter than six months since the beginning of the project.~* drug users and alcoholics not in rehabilitation~* people with serious mental health problems~* people who do not speak English as a first language.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Transcendental Meditation training (Type: EXPERIMENTAL): The intervention of the project is the teaching and learning of Transcendental Meditation technique. The technique involves the use of a sound (mantra) to effortlessly allow the mind to settle down to a state of inner calm. It is a simple, natural and effortless practise, and unlike other meditation strategies, it does not involve concentration or control of the mind. The practice does not require any religion, philosophy, or change in lifestyle. Once learned the technique, participants will practice it twice a day, 20 minutes every morning and 20 minutes in the afternoon.
- control (Type: NO_INTERVENTION): no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimised Procedure in Patients With NSTEMI and CKD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* patient with an acute NSTEMI~* patient with a GRACE score \< 140~* patient with an acute or a chronic kidney disease (stage 1 - 5)~* patient who agree with the randomized assignment to one of the study groups in written~* signed Informed content prior to study inclusion~* patient who are legally competent at the time of study inclusion~Exclusion Criteria:~* pregnancy~* nursing women~* patient has been committed to an institution by legal or regulatory order~* Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study~* participation in a parallel clinical trial~* subjects who are in any state of dependency to the investigators

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- group A (Type: EXPERIMENTAL): direct coronary angiography
- group B (Type: EXPERIMENTAL): direct coronary angiography plus ischemic precondition
- group C (Type: EXPERIMENTAL): delayed coronary angiography; the kidneys will be irrigated prior to coronary angiography
- group D (Type: EXPERIMENTAL): delayed coronary angiography plus ischemic precondition; the kidneys will be irrigated prior to coronary angiography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion:~Patients must be at least 18 years of age. Histologically confirmed (including immunohistochemistry) diagnosis of T-Cell Lymphoma by skin biopsy or visceral/lymph node biopsy or bone marrow aspirate/biopsy Life expectancy of more than 3 months.~Exclusion:~Uncontrolled diabetes mellitus Active or serious infections uncontrolled with antibiotics Concurrent treatment, radiation or investigational treatment. 5.2.6 Significant underlying cardiac disease, including unstable angina, myocardial infarction less than 6 months before starting study, congestive failure of any cause

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: pancreatic adenocarcinoma without distant metastasis; patients \> 18 years~Exclusion Criteria: distant metastasis and pancreatic adenocarcinoma

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Genomic Landscape of Ceritinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Diagnosis of metastatic stage IIIB/IV lung adenocarcinoma.~* Presence of known ALK gene rearrangement.~* Consented to HRPO# 201305031 (Tissue and Blood Acquisition for Genomic Analysis and Collection of Health Information from Patients with Thoracic Malignancies, Suspected Thoracic Malignancies, or Mesothelioma) with an existing specimen prior to initiation of treatment with ceritinib.~* At least 18 years of age.~* Received treatment with standard of care ceritinib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Seizure Prophylaxis in Aneurysm Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (≥18 years)~2. Presence of intracranial aneurysm (without rupture)~3. Treating surgeon has recommended surgical repair of the aneurysm.~Exclusion Criteria:~1. History of seizures within last 10 years~2. History of epilepsy~3. History of prior stroke~4. Currently prescribed medication with anti-epileptic activity (keppra,dilantin, tegretol, lamictal, topamax, etc.)~5. Brain tumor~6. Pregnant or nursing woman~7. Known levetiracetam allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: ACTIVE_COMPARATOR): None
- No anti-epileptic treatment (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Retrospective Study of the Role of Thiazolidinediones to Reduce the Incidence of Atrial Arrhythmias

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~All patient who underwent elective cardiac Surgery in the Emory University Hospital, Crawford Long Hospital, or the Va Medical Center between 2000-2005.-~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 15.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with high cholesterol levels either not receiving or willing and able to discontinue ongoing lipid-lowering therapy~Exclusion Criteria:~* LDL-C levels \> 250 mg/dL (6.48 mmol/L)~* Triglycerides levels \> 350mg/dL (3.95 mmol/L)~* Conditions / situations such as:~  * presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels~ * Active liver disease~ * High estimated risk of Coronary Heart Disease~ * Recent history of congestive heart failure , of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or severe peripheral artery disease~ * Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or Known to be Human Immunodeficient Virus (HIV) positive~* Pregnant or breast-feeding women,~* Women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the Investigational Product~* Hypersensitivity to any component of atorvastatin~* Concurrent administration of Cytochrome P450 3A4 inhibitors (e.g. cyclosporine, erythromycin, clarithromycin, and azole antifungals) should be avoided as increasing the risk of myopathy with atorvastatin~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): AVE5530 25mg
- 3 (Type: EXPERIMENTAL): AVE5530 50mg
- 4 (Type: ACTIVE_COMPARATOR): atorvastatin 10mg
- 5 (Type: EXPERIMENTAL): atorvastatin 10mg + AVE5530 25mg
- 6 (Type: EXPERIMENTAL): atorvastatin 10mg + AVE5530 50mg
- 7 (Type: ACTIVE_COMPARATOR): atorvastatin 20mg
- 8 (Type: EXPERIMENTAL): atorvastatin 20mg + AVE5530 25mg
- 9 (Type: EXPERIMENTAL): atorvastatin 20mg + AVE5530 50mg
- 10 (Type: ACTIVE_COMPARATOR): atorvastatin 40mg
- 11 (Type: EXPERIMENTAL): atorvastatin 40mg + AVE5530 25mg
- 12 (Type: EXPERIMENTAL): atorvastatin 40mg + AVE5530 50mg
- 13 (Type: ACTIVE_COMPARATOR): atorvastatin 80mg
- 14 (Type: EXPERIMENTAL): atorvastatin 80mg + AVE5530 25mg
- 15 (Type: EXPERIMENTAL): atorvastatin 80mg + AVE5530 50mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy